N,N,2-三甲基丁烷-2-胺 | 57757-60-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N,N,2-三甲基丁烷-2-胺
• 英文名称: tert-Amyldimethylamin
• 英文别名: dimethyl-tert-pentyl-amine；2-Dimethylamino-2-methyl-butan；Dimethyl-(α.α-dimethyl-propyl)-amin；Dimethyl-tert.-amyl-amin；N,N,2-Trimethylbutan-2-amine
• CAS: 57757-60-5
• 化学式: C₇H₁₇N
• 分子量: 115.219
• InChiKey: CUHMMDPUXJFCNB-UHFFFAOYSA-N

物化性质

• 沸点：
  115 °C
• 密度：
  0.761±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2921199090

反应信息

• 作为反应物：
  描述：

  N,N,2-三甲基丁烷-2-胺 在 2,6-二甲基吡啶 、 乙醚 作用下， 生成 2-甲基-丁烯
  参考文献：
  名称：

  Steric Effects in Elimination Reactions. X. Steric Strains as a Factor in Controlling the Direction of Bimolecular Eliminations. The Hofmann Rule as a Manifestation of Steric Strain

  摘要：

  DOI：

  10.1021/ja01591a050
• 作为产物：
  描述：

  2-甲基-2-丁醇 在 硫酸 、 溶剂黄146 作用下， 生成 N,N,2-三甲基丁烷-2-胺
  参考文献：
  名称：

  Steric Effects in Elimination Reactions. X. Steric Strains as a Factor in Controlling the Direction of Bimolecular Eliminations. The Hofmann Rule as a Manifestation of Steric Strain

  摘要：

  DOI：

  10.1021/ja01591a050

文献信息

• [EN] SOLVENTS<br/>[FR] SOLVANTS
  申请人：BIONIQS LTD

  公开号：WO2009034329A1

  公开（公告）日：2009-03-19

  There is described the use of a protic ionic liquid comprising a trialkylammonium salt as a solvent.

  这里描述了一种包含三烷基铵盐的质子离子液体作为溶剂的使用。
• HPK1 ANTAGONISTS AND USES THEREOF
  申请人：Nimbus Saturn, Inc.

  公开号：US20210078996A1

  公开（公告）日：2021-03-18

  The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.

  本发明提供了化合物、其组合物以及使用这些化合物用于抑制HPK1和治疗HPK1介导的疾病的方法。
• CTGF EXPRESSION INHIBITOR
  申请人：Shionogi Co., Ltd.

  公开号：EP1839655A1

  公开（公告）日：2007-10-03

  A CTGF expression inhibitor comprising a compound of the formula I: a pharmaceutically acceptable salt or solvate thereof as an active ingredient, (wherein Y is hydroxy or a group of the formula: -NH-SO2-Y' (wherein Y' is optionally substituted aryl or optionally substituted alkyl), and R1 to R9 are each independently hydrogen, halogen, optionally substituted alkyl, optionally substituted alkoxy or the like).

  一种CTGF表达抑制剂，包括以下公式I的化合物：作为活性成分的药用可接受的盐或溶剂（其中Y为羟基或具有以下结构的基团：-NH-SO2-Y'（其中Y'为可选择取代的芳基或可选择取代的烷基），R1至R9分别独立地为氢、卤素、可选择取代的烷基、可选择取代的烷氧基或类似物）。
• Heteroaromate OSC inhibitors
  申请人：Aebi Johannes

  公开号：US20070099985A1

  公开（公告）日：2007-05-03

  The present invention relates to heteroaromate OSC inhibitors. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with 2,3-oxidosqualene-lanosterol cyclase such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, gallstones, tumors and/or hyperproliferative disorders, and treatment and/or prophylaxis of impaired glucose tolerance and diabetes.

  本发明涉及杂环芳香族OSC抑制剂。该化合物可用于治疗和/或预防与2,3-氧化甾醇-鲨烯环化酶相关的疾病，如高胆固醇血症、高脂血症、动脉硬化、血管疾病、真菌感染、胆结石、肿瘤和/或增生性疾病，以及治疗和/或预防糖耐量受损和糖尿病。
• Norvaline Derivative and Method for Preparation Thereof
  申请人：Harada Naoyuki

  公开号：US20080076769A1

  公开（公告）日：2008-03-27

  Norvaline derivative of the formula [I] or pharmaceutically acceptable salt thereof, method for preparing the same, pharmaceutical composition containing the same, and use of said compound for inhibiting transporting activity of glycine transporter type 2 (GlyT2). [wherein X is —CH 2 —, —O—, —S— or single bond; Ar is optionally substituted aryl or lower cycloalkyl; n is 0 to 2; R 1 and R 2 are (i) each is hydrogen or lower alkyl; (ii) R 1 and R 2 are combined to form lower alkylene; or (iii) R 1 is hydrogen or lower alkyl and R 2 is combined with R 4 or R 6 to form lower alkylene; R 3 and R 4 are (i) each is hydrogen or lower alkyl; (ii) R 3 and R 4 are combined to form lower alkylene; or (iii) R 3 is hydrogen or lower alkyl and R 4 is combined with R 2 or R 6 to form lower alkylene; R is or —OR 7 ; R 5 and R 6 are (i) each is optionally substituted lower alkyl, or hydrogen; (ii) R 5 and R 6 are combined to form aliphatic 5- to 6-membered heterocyclic group; or (iii) R 5 is optionally substituted lower alkyl or hydrogen and R 6 is combined with R 2 or R 4 to form lower alkylene; R 7 is lower alkyl.

  Norvaline衍生物的化学式[I]或其药学上可接受的盐，制备方法，含有该化合物的药物组合物，以及用于抑制甘氨酸转运体2型（GlyT2）的转运活性的用途。[其中X为-CH2-，-O-，-S-或单键；Ar为可选取代芳基或较低的环烷基；n为0至2；R1和R2为（i）氢或较低的烷基；（ii）R1和R2结合形成较低的烷基；或（iii）R1为氢或较低的烷基，R2与R4或R6结合形成较低的烷基；R3和R4为（i）氢或较低的烷基；（ii）R3和R4结合形成较低的烷基；或（iii）R3为氢或较低的烷基，R4与R2或R6结合形成较低的烷基；R为-OH或-OR7；R5和R6为（i）可选取代的较低烷基或氢；（ii）R5和R6结合形成脂肪族5-至6-成员杂环基；或（iii）R5为可选取代的较低烷基或氢，R6与R2或R4结合形成较低的烷基；R7为较低烷基。